OA01.04 Safety and Efficacy of Flu Vaccination After Treatment with Immune Checkpoint Inhibitors: a Retrospective Review

Roberts, Nathan B.; Dothard, Andy; Ahmed, Tamjeed; Petty, W. Jeffrey; Ruiz, Jimmy; Lycan, Thomas

doi:10.1016/j.jtho.2019.09.019

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Among 1046 articles initially retrieved, 25 were found to fulfill the inclusion criteria and were included in the systematic review 19,20,29–50. Fourteen studies were peer-reviewed19,20,29–40 and 11 nonpeer-reviewed (conference abstracts) 41–50. Main characteristics along with schematic presentation of main results of studies included in the systematic review are presented in Supplementary Table 1 and Supplementary Table 2, Supplemental Digital Content 1, http://links.lww.com/JIT/A670.…”

Section: Resultsmentioning

confidence: 99%

“…19,20, Fourteen studies were peer-reviewed 19,20,[29][30][31][32][33][34][35][36][37][38][39][40] and 11 nonpeer-reviewed (conference abstracts). [41][42][43][44][45][46][47][48][49][50] Main characteristics along with schematic presentation of main results of studies included in the systematic review are presented in Supplementary Table 1 and Supplementary Table 2, Supplemental Digital Content 1, http://links.lww.com/JIT/A670. Most studies were conducted in the USA (10 articles/conference abstracts) and Italy (5 articles/conference abstracts).…”

Section: Literature Search and Inclusion Of Studiesmentioning

confidence: 99%

“…2). Five studies reported the incidence of serious irAEs 30,33,38,42,45 and the respective pooled OR in influenza vaccinated versus nonvaccinated patients was 0.59 (95% CI: 0.32-1.08, P = NS), (Fig. 3).…”

Section: Secondary Endpointsmentioning

confidence: 99%

See 3 more Smart Citations

Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Tsiakos

Kyriakoulis

et al. 2022

Journal of Immunotherapy

View full text Add to dashboard Cite

The safety and efficacy of influenza vaccination is not well-studied in cancer patients receiving immune checkpoint inhibitors (ICIs). A systematic review and meta-analysis was performed aiming to summarize available data regarding influenza vaccination in ICI-treated cancer patients. Peer-reviewed studies or nonpeer-reviewed conference abstracts including ICI-treated cancer patients who received at least 1 dose of influenza vaccine were deemed eligible. A systematic search in PubMed/EMBASE was performed until October 26, 2021. Endpoints of interest included mortality as the primary outcome and secondary safety outcomes such as the incidence of immune-related adverse events (irAEs). Twenty-five studies were included in the systematic review, among which 9 were included in the meta-analysis. Meta-analysis of 3 studies (n=589, weighted age 64 y, men 61%, influenza vaccinated 32%) showed pooled odds ratio for death in influenza vaccinated versus nonvaccinated patients at 1.25 [(95% confidence intervals (CI): 0.81–1.92), P=non significant (NS)]. Meta-analysis of 6 studies studies (n=1285, weighted age 60 y, men 59%, influenza vaccinated 48%) showed pooled odds ratio for any irAEs in influenza vaccinated versus nonvaccinated patients at 0.82 [95% CI: 0.63–1.08, P=NS]. Similar results were observed in sensitivity analyses for serious irAEs, as well as when only peer-reviewed studies were included. Influenza vaccination appears to be a safe and reasonable intervention for cancer patients receiving ICIs. Most data are derived from retrospective observational studies. Randomized studies are needed to provide high-quality evidence.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Literature Search and Inclusion Of Studiesmentioning

confidence: 99%

Section: Secondary Endpointsmentioning

confidence: 99%

See 2 more Smart Citations

Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Tsiakos

Kyriakoulis

et al. 2022

Journal of Immunotherapy

View full text Add to dashboard Cite

show abstract

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases

Retnakumar

Chauvin

Bayry

2023

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

The potential increased risk of immune-related adverse events (irAEs) post-influenza vaccine is a concern in patients receiving immune checkpoint inhibitors (ICI). We conducted a systematic review with meta-analysis of studies reporting the effects of influenza vaccination in patients with cancer during ICI treatment. We searched five electronic databases until 01/2022. Two authors independently selected studies, appraised their quality, and collected data. The primary outcome was the determination of pooled irAE rates. Secondary outcomes included determination of immunogenicity and influenza infection rates and cancer-related outcomes. Nineteen studies (26 publications, n = 4705) were included; 89.5% were observational. Vaccinated patients reported slighter lower rates of irAEs compared to unvaccinated patients (32% versus 41%, respectively). Seroprotection for influenza type A was 78%–79%, and for type B was 75%. Influenza and irAE-related death rates were similar between groups. The pooled proportion of participants reporting a laboratory-confirmed infection was 2% (95% CI 0% to 6%), and influenza-like illness was 14% (95% CI 2% to 32%). No differences were reported on the rates of laboratory-confirmed infection between vaccinated and unvaccinated patients. Longer progression-free and overall survival was also observed in vaccinated compared with unvaccinated patients. Current evidence suggests that influenza vaccination is safe in patients receiving ICIs, does not increase the risk of irAEs, and may improve survival.

show abstract

OA01.04 Safety and Efficacy of Flu Vaccination After Treatment with Immune Checkpoint Inhibitors: a Retrospective Review

Cited by 3 publications

References 0 publications

Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis

Contact Info

Product

Resources

About